TG Therapeutics looks like a one-product story, and growing pressure from insurers, regulators, and rivals could squeeze what it can charge and slow how fast it can expand. The big question is whether strong demand, new ways to take its key medicine, and efforts to broaden the pipeline can outweigh looming pricing and patent threats.Read more
A newer multiple sclerosis treatment from TG Therapeutics could spread faster than many expect as insurers and patients increasingly prefer easier, at-home options. The big question is whether that momentum can last while the company leans heavily on one flagship drug amid pricing pressure, regulation, and tougher competition.Read more
TG Therapeutics is betting big on BRIUMVI, with a new at-home injection version and wider insurance coverage that could bring in many more people with multiple sclerosis. But with so much riding on one medicine, tougher competition and payer pressure could quickly change the story.Read more
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
